<DOC>
	<DOCNO>NCT00274768</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well capecitabine work treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Capecitabine Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient metastatic breast cancer treat fixed-dose capecitabine . Secondary - Determine clinical benefit , time treatment failure ( TTF ) , safety , toxicity profile regimen patient . - Determine pharmacokinetics ( PK ) pharmacogenetics patient . - Correlate pharmacodynamic effect drug toxicity response patient . - Determine compliance adherence regimen correlate PK parameter patient . OUTLINE : This open-label study . Patients receive fixed-dose oral capecitabine twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 45 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis adenocarcinoma breast Evidence metastatic involvement ( stage IV disease ) Patients must measurable disease At least one measurable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) Treated brain metastasis ( surgery radiation therapy ) allow clinically stable Patients leptomeningeal disease ineligible Hormone receptor status : Not specify PATIENT CHARACTERISTICS : ECOG ( Eastern Cooperative Oncology Group ) performance status 02 Male female Menopausal status specify Absolute neutrophil count ( ANC ) ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine clearance &gt; 50 mL/min Fertile patient must use effective contraception No history another severe and/or lifethreatening medical disease No active primary malignancy Not pregnant nursing Negative pregnancy test Patients asymptomatic HIV infection eligible Liver dysfunction score ≤ 9 No preexisting liver disease ( i.e. , cirrhosis active viral hepatitis ) No active gastrointestinal malabsorption illness No clinically significant cardiac disease , include follow : Congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia well control medication , myocardial infarction within past six month No prior unanticipated severe reaction fluoropyrimidine therapy , know hypersensitivity fluorouracil , know dihydropyrimidine dehydrogenase deficiency No history uncontrolled seizure central nervous system disorder No significant history noncompliance medical regimens No clinically significant psychiatric disability would preclude study compliance PRIOR CONCURRENT THERAPY : No previous capecitabine Up 3 prior cytotoxic regimen allow metastatic disease Prior noncytotoxic therapy allow ( e.g. , hormonal treatment trastuzumab ) No concurrent therapy intend treat primary condition include chemotherapy , biologic agent , immunotherapy No concurrent antiestrogen therapy , radiation therapy , investigational systemic therapy No concurrent investigational drug No concurrent use follow drug : warfarin full anticoagulation , cimetidine , azidothymidine ( AZT ) Minidose warfarin prophylaxis central venous catheter thrombosis allow At least 4 week since prior sorivudine brivudine Concurrent use bisphosphonates allow initiated beginning study therapy Concurrent use megestrol acetate suspension appetite stimulant allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>